European Medicines Agency Recommends Revocation Of Marketing Authorisations For Bufexamac
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that marketing authorisations for bufexamac-containing medicines be revoked. The CHMP recommendations follow a scientific review, which identified a high risk of sometimes serious contact allergic reactions with bufexamac…
(more...)